Cancer Progress 2017

Tuesday, March 7, 2017
7:00 – 8:00am Registration and Continental Breakfast
8:00 – 8:15am Opening Remarks
 Audio File: 
  • Jeff Bockman, PhD, VP, Defined Health
8:15 – 9:15am Keynote: Walking on the Moon: Reflections on the Future of Cancer
Greg Simon, JD, Executive Director of the Biden Cancer Initiative of the Biden Foundation; Former Executive Director of the White House Cancer Moonshot Task Force
Audio file: 
9:15 – 10:30am Microbiome and IO: All Things Great and Small
Moderator: Jeffrey M. Bockman, PhD, Senior Vice President, Head of Oncology Practice, Defined Health
Audio file: 
Panelists:

  • Luisa Salter-Cid, PhD, VP, Head Immunoscience, Small Molecule Immuno-Oncology & Genomics Discovery, Bristol-Myers Squibb
  • Gregory Sieczkiewicz, JD, PhD, Managing Director & Chief IP Counsel, MPM Capital
  • Laurence Zitvogel, MD, PhD, Group Leader, Tumor Immunology and Immunotherapy, Institute Gustav Roussy
10:30 – 11:00am Networking Break
11:00 – 12:15pm Challenges of IO Drug Development and Commercialization: To PD or Not to PD? And How? Those are the Questions
Moderator: Bruce L. Booth, D. Phil., Partner, Atlas Venture
Audio file:
Panelists:

  • Jeffrey H. Hanke, PhD, Executive Vice President, R&D and Chief Scientific Officer, TESARO
  • Robert Hershberg, MD, PhD, Chief Scientific Officer, Celgene Corporation
  • Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
  • Alexander Shoushtari, MD, Assistant Attending Physician, Memorial Sloan Kettering Cancer Center
12:15 – 1:30pm Networking Luncheon
1:30 – 2:45pm Future Role of Non-IO Therapies: The Sad Tale of Neglected Targets and Companies in the Race to IO Domination
Moderator: Joel S. Sandler, PhD, Associate Principal, Defined Health
Audio file:
Panelists:

  • Lewis H. Bender, MS, MA, MBA, President and Chief Executive Officer, Intensity Therapeutics, Inc.
  • Axel Hoos, MD, PhD, Senior Vice President, Therapeutic Area Head R&D, Head Immuno-Oncology, GlaxoSmithKline
  • Russell LaMontagne, MS, President and Chief Executive Officer, Boston Immune Technologies and Therapeutics
  • Eric Rowinsky, MD, Executive Chairman and President, Rgenix, Inc.
  • Peter Sandor, MD, MBA, Vice President and Global TA Head Oncology, Marketing Strategy, Astellas Pharma, US, Inc.
2:45 – 4:00pm Data, Data Everywhere: How to Think About, Interpret and Present the Facts
Moderator: Mark Simon, Partner, Torreya Partners
Audio file: 
Panelists:

  • Kapil Dhingra, MD, Managing Member, KAPital Consulting, LLC
  • Robert H. Glassman, MD, Vice Chairman, Credit Suisse Global Health Care Investment Banking
  • Mark J. Ratain, MD, Leon O. Jacobson, Professor of Medicine, University of Chicago
  • Neal Rosen, MD, PhD, Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center
4:00 – 4:15pm Networking Break
4:15 – 5:30pm Lung Cancer: The Times They Are a Changin’
Moderator: James Lee, PhD, Senior Consultant, Defined Health
Audio file: 
Panelists:

  • Maria Koehler, MD, PhD, Vice President, Strategy, Innovation and Collaborations, Pfizer
  • Gregory Lubiniecki, MD, Executive Director, Clinical Research Oncology, Merck Research Laboratories
  • Charles Rudin, MD, PhD, Chief Thoracic Oncology Service; Sylvia Hassenfeld Chair in Lung Cancer Research; co-Director, Druckenmiller Center for Lung Cancer Research; Professor of Medicine, WCMC
  • Steve Worland, PhD, President and Chief Executive Officer, eFFECTOR
5:30 – 7:30pm Cancer Progress 2016 Reception
Wednesday, March 8, 2017
7:00 – 8:00am Continental Breakfast
8:00 – 8:15am Opening Remarks
Audio file: 
8:15 – 9:45am Aging and Cancer: Live and Let Die or a Cancer-Free Methuselah?
Moderator: Mike Rice, MS, MBA, Principal, Defined Health
Panelist:

  • Judith Campisi, PhD, Professor, Buck Institute for Research on Aging
  • James DeGregori, PhD, Professor, Dept. of Biochemistry and Molecular Genetics; Courtenay C. and Lucy Patten Davis Endowed Chair in Lung Cancer Research; Deputy Director for Basic Science, University of Colorado Cancer Center
Audio file: 
9:45 – 10:00am Networking Break
10:00 – 11:15am Treating the Enigmatic Exceptional Responders
Moderator: Mike Rice, MS, MBA, Principal, Defined Health
Audio file: 
Panelists:

  • Isaac Kohane, MD, PhD, Marion V. Nelson Professor & Chair, Department of Biomedical Informatics, Harvard Medical School
  • Eric D. Perakslis, PhD, Senior Vice President, Informatics, Takeda Pharmaceuticals
  • David Solit, MD, Director, Developmental Therapeutics, Memorial Sloan Kettering Cancer Center
11:15 – 12:30pm Novel Modalities: Viruses as Cancer Therapeutics – Converting Bad to Good
Moderator: Jeffrey M. Bockman, PhD, Vice President, Defined Health
Audio file:
Panelists:

  • John Beadle, MD, Chief Executive Officer, PsiOxus Therapeutics Ltd
  • John C. Bell PhD, Senior Scientist, Ottawa Hospital Research Institute, University of Ottawa
  • Robert Coffin, PhD, Chief Executive Officer & Director, Replimune
  • Noriyuki Kasahara, MD, PhD, Professor, Departments of Cell Biology & Pathology Co-Leader, Viral Oncology Program, University of Miami (and consultant to Tocagen)
12:30 – 1:45pm Networking Luncheon
1:45 – 3:00pm Clinical Trials and Approvals 3.0: How Will New Therapeutic Entities be Developed and Approved in 2025?
Moderator: Brian Leyland-Jones, MB BS, PhD, Vice President, Avera Center for Precision Oncology and the Department of Molecular and Experimental Medicine, Avera Cancer Institute, Consulting Professor, Stanford University School of Medicine
Audio file:
Panelists:

3:00 – 4:15pm Cancer Drug Pricing: Valuing the Value of Innovation
Moderator: Ed Saltzman, Chairman, Defined Health
Audio file:
Panelists:

  • Peter Bach, MD, Director, Center for Health Policy and Outcomes, Memorial Sloan Kettering Cancer Center
  • Roy Beveridge, MD, Chief Medical Officer, Humana
  • Roger Longman, CEO, Real Endpoints LLC
  • Scott Shortenhaus, Director of Advocacy, Professional Relation & Policy, Lilly
4:15pm Cancer Progress 2017 Conference Concludes